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Mesenchymal stem cells (MSCs) have a large potential in cell therapy for treatment of 
inflammatory and autoimmune diseases, thanks to their immunomodulatory properties. 
The encouraging results in animal models have initiated the translation of MSC therapy 
to clinical trials. In cell therapy protocols with MSCs, administered intravenously, several 
studies have shown that a small proportion of infused MSCs can traffic to the draining 
lymph nodes (LNs). This is accompanied with an increase of different types of regulatory 
immune cells in the LNs, suggesting the importance of migration of MSCs to the LNs 
in order to contribute to immunomodulatory response. Intranodal (IN), also referred as 
intralymphatic, injection of cells, like dendritic cells, is being proposed in the clinic for 
the treatment of cancer and allergy, showing that this route of administration is clinically 
safe and efficient. In this study, we investigated, for the first time, the biodistribution 
and the efficacy of Luciferase+ adipose-derived MSCs (Luci-eASCs), infused through the 
inguinal LNs (iLNs), in normal mice and in inflamed mice with colitis. Most of the Luci-
eASCs remain in the iLNs and in the adipose tissue surrounding the inguinal LNs. A small 
proportion of Luci-eASCs can migrate to other locations within the lymphatic system and 
to other tissues and organs, having a preferential migration toward the intestine in colitic 
mice. Our results show that the infused Luci-eASCs protected 58% of the mice against 
induced colitis. Importantly, a correlation between the response to eASC treatment and 
a higher accumulation of eASCs in popliteal, parathymic, parathyroid, and mesenteric 
LNs were found. Altogether, these results suggest that IN administration of eASCs is 
feasible and may represent an effective strategy for cell therapy protocols with human 
adipose-derived MSCs in the clinic for the treatment of immune-mediated disorders.
Keywords: adipose-derived mesenchymal stem cells, intranodal therapy, colitis, biodistribution, efficacy, 
immunomodulation
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inTrODUcTiOn
Mesenchymal stem cells (MSCs) are multipotent adult stem cells 
capable of self-renewal and differentiation into multiple cell lin-
eages of mesodermal origin such as chondrocytes, adipocytes, 
and osteocytes (1). These cells have been identified in multiple 
tissues such as bone marrow (2), umbilical cord blood (3), 
amniotic fluid (4), adipose tissue (5), dental pulp (6), and among 
others. MSCs are considered as a novel modality of therapy for 
a wide variety of degenerating and immunological disorders 
(1, 2, 7, 8). The encouraging results in animal models have initi-
ated the translation of MSC therapy in clinical trials in a range 
of immunomediated diseases such as graft versus host disease 
(9), inflammatory bowel disease (10–12), multiple sclerosis (13), 
systemic lupus erythematosus (14, 15), rheumatoid arthritis 
(16–20), and among others. The immunomodulatory capacity 
of MSCs takes place both by direct cell-to-cell contact and by 
means of soluble factors (21). At present, it is unknown whether 
the therapeutic effects of MSCs are carried out by a small fraction 
of the administered MSCs that migrates to sites of inflammation 
or/and through distant induction of regulatory immune cells 
that mediate immunomodulation and tissue repair (22). There 
are controversial data regarding the presence of MSCs at site of 
inflammation (23–25). In any case, their therapeutic effects are 
linked to a final increase of myeloid and lymphoid cells with a 
regulatory phenotype in the secondary lymphoid tissues associ-
ated to the inflammation site (18, 19, 25, 26). Thus, in this study 
(27), we hypothesized that intranodal (IN) administration of 
MSCs could be feasible and would represent an alternative route 
for modulating immune responses (18, 25, 28). IN administra-
tion treatments are being extensively used in clinical trials for 
the treatment of cancer (29–32) and allergy (33, 34), indicating 
that this route of administration is feasible in humans and can 
be applied to the clinic. Data from clinical trials show that IN 
therapy is easy, practically painless, safe and is associated with 
a low risk of systemic adverse effects (35–37). Additionally, 
Gil-Ortega et  al. provided robust evidences that endogenous 
adipose-derived MSCs (eASCs) can navigate through the lym-
phatic system (28). At present, IN administration of MSCs has 
not been assessed previously, whereas intravenous administra-
tion of MSCs has been used in many experimental models and 
in clinical trials. However, the intravenous injection of MSCs is 
thought to be limited by cell entrapment in the lungs (24, 38). 
This might limit the bioavailability of the cells, their trafficking 
to tissues and, possibly, their therapeutic effects (24). Local 
administration of MSCs is of interest in  situations where they 
can be directly implanted in the injured tissues trying to improve 
their beneficial effects (39–42). The number of MSCs that can 
be delivered inside the lymph node (LN) after IN administra-
tion could be significantly greater than the number of cells that 
reach the LNs following their delivery through the blood stream, 
either through intravenous or intraperitoneal administration. 
This may allow achieving robust therapeutic effects while poten-
tially reducing the cell dose of MSCs required for modulating 
inflammation.
In this study, we aimed to examine the biodistribution of 
human Luciferase+ eASCs (Luci-eASCs) after IN administration 
in steady state and following an acute inflammatory challenge in 
the colon with the haptenizing reagent trinitrobenzene sulfonic 
acid (TNBS). Strikingly, modulation of intestinal inflammation 
was observed. In parallel to this study, we also demonstrate that 
IN infusion of eASCs can modulate ongoing acute inflamma-




C57/BL6 male mice of 6–8 weeks of age were obtained from Charles 
River (Burlington, MA, USA). All experiments were performed in 
accordance with the corresponding regulations regarding experimen-
tal animal welfare (RD 223/1998 and Directive 2010/63/EU protocols).
generation of human expanded adipose-
Derived Mscs
Human samples were obtained after informed consent as 
approved by the Spanish Ethics Committee of reference for the 
site of tissue procurement (Clínica de la Luz Hospital, Madrid, 
Spain). Human adipose tissue aspirates from healthy donors 
were processed as described elsewhere (18). All the eASCs used 
fulfilled the release criteria of identity, purity, and potency needed 
for their clinical use.
generation of luci-eascs
Reporter Luciferase-EGFP bicistronic retroviral vector was con-
structed using standard cloning procedures. The H2B gene was 
amplified by PCR (forward, TATGGGTACCGCCACCATGCCA 
GAGCCAGCGAAG; reverse, TATGGATCCTTAGCGCTGGTG 
TACTTG) and cloned into pCopGFP2i-N (Evrogen, Moscow, 
Russia) using Acc65I–BamHI sites. Internal ribosome entry 
site (IRES) element was isolated from pIRES2-EGFP (Clontech, 
Mountain View, CA, USA) using SalI–MscI and cloned upstream 
H2B-CopGFP2i into SalI–Acc65I (Klenow blunted) sites. 
Luciferase was cut from pGL2 Basic (Promega, Madison, WI, 
USA), using XhoI–XbaI (Klenow blunted) restriction sites, 
and inserted upstream IRES-H2B-CopGFP2i into XhoI–SalI 
(Klenow blunted). CopGFP2i was then replaced by EGFP, from 
pEGFP-N1 (Clontech) using AgeI–NotI sites. The Luciferase-
IRES-H2B-EGFP cassette was separated using BglII–NotI and 
cloned into BamHI–NotI sites of pRV retroviral vector to give 
the final pRV-Luciferase-IRES-H2B-EGFP bicistronic reporter 
construction. Transfection and generation of viral supernatants 
were performed using polyethylenimine (1 vol PEI:2 vol DNA). 
Viral supernatants were used for infection of eASCs. For infection, 
eASCs were seeded in 6-well plates and infected with retroviral 
particles concentrated when cell confluency was between 70 and 
80%. Finally, the transduction was evaluated by flow cytometry 
(FACS Calibur™, BD Bioscience, San Diego, CA, USA), selecting 
clones with 90% expression of EGFP by cell sorting.
immunophenotyping of luci-eascs
Luci-eASCs were defined according to the criteria of the 
International Society for Cellular Therapy (43). Luci-eASCs were 
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characterized by their immunophenotype; positive for CD73 
(AD2), CD90 (5E10, both from Becton Dickinson), and CD105 
(43A3, from Biolegend) and negative for CD14 (RM052, from 
Immunotech), CD34 (8G12, from Becton Dickinson), CD45 
(J33, from Beckman Coulter), and HLA-DR (AF6-120.1, from 
eBiosciences).
immunosuppression assay  
of luci-eascs
Buffy coats were provided by the National Transfusion Centre of 
the Comunidad Autonoma of Madrid. Peripheral blood mono-
nuclear cells (PBMCs) were isolated by density centrifugation 
gradient using Ficoll-Paque Plus (GE Healthcare Biosciences AB, 
Uppsala, Sweden) following the supplier’s protocol. Purity was 
verified by flow cytometry.
For CFSE labeling, PBMCs were washed extensively to 
remove fetal bovine serum (FBS), resuspended in a 10 µM CFSE 
(Carboxyfluorescein diacetate N-succinimidyl ester, Sigma-
Aldrich, St. Louis, MO, USA) solution (107 PBMC per 200 µL 
of solution), and incubated under constant shaking at 37°C 
for 10 min. Reaction was stopped by adding ice-cold medium 
(RPMI + 10% FBS), and cells were washed three times with ice-
cold phosphate buffer saline. Cells were then cultured overnight 
and one aliquot was used to set up and control the FL-1 voltage 
for CFSE. After resting overnight, CFSE-labeled PBMCs were 
activated with the Pan T Cell Activation Kit (microbeads coated 
with anti-CD3, anti-CD2, and anti-CD28; Miltenyi Biotech, 
Auburn, CA, USA) following the manufacturer’s instructions. 
PBMCs (106  cells/well) were cultured in 24-well plates alone 
or with Luci-eASCs (4 × 104 cells/well; Luci-eASC:PBMC ratio 
1:25) in a total volume of 1 mL of RPMI + 10% FBS. The 1:25 
ratio was chosen because it provided a high inhibitory effect, on 
the basis of previous studies (44, 45). After 5 days, PBMCs were 
harvested and labeled with 7-AAD and anti-CD3 antibody, and 
cell proliferation of the CD3+/7-AAD− population (viable CD3 
T lymphocytes) was determined by flow cytometry, according to 
loss of CFSE signal. Data were analyzed with the use of FCSExpress 
4 (De Novo Software, Glendale, CA, USA) and BD CellQuest™ 
Pro analysis (Becton Dickinson) softwares. CaliBRITE beads 
(BD Bioscience, Erembodegem-Aalst, Belgium) were used 
before each assay to calibrate the cytometer.
induction and evaluation of colitis after 
Treatment with luci-eascs
To induce colitis, male C57BL/6 mice (6–8 weeks old) were preim-
munized on their shaved back with 1% of TNBS (Sigma-Aldrich, 
St. Louis, MO, USA) in a mixture of acetone:olive (4:1 v/v). After 
1 week, colitis was induced by intrarectal administration of 3 mg 
of TNBS in 50% ethanol (100  µL) per mouse. 1  h after TNBS 
administration, 3.2 × 105 of Luci-eASCs per mouse were adminis-
tered IN, by injection of the cell suspension in the iLNs (1.6 × 105 
cells in both the right and the left iLNs). As controls, healthy mice 
infused with the Luci-eASC and mice treated with intrarectal 50% 
EtOH only (vehicle of the TNBS) and infused with Luci-eASC 
IN were used. Score of colitis (weight of mice, stools, and general 
aspect of mice) was monitored for 48 h.
In Vivo Optical Bioluminescence imaging
Bioluminescent imaging analysis was conducted at 48  h after 
the infusion of Luci-eASCs with the IVIS 200 imaging system 
(Caliper, Hopkinton, MA, USA).
Whole-body bioimaging analysis was done in anesthetized 
mice. The bioimaging analysis in main tissues and organs 
(liver, spleen, intestine, lungs, heart, and blood), secondary LNs 
(popliteal, popLN; parathymic, thymLN; parathyroid, thyrLN; 
mesenteric, mLN; caudal, cLN; axillary, axLN; and inguinal, 
iLN, LNs) and the adipose tissue around the inguinal LNs, where 
the Luci-eASCs were injected, were determined immediately 
after culling the mice. Photons emitted were acquired as photons 
per s/cm2 per steradian using Living Imaging 3.0 (Caliper). For 
photon quantification, a region of interest was manually selected 
and kept constant within each experiment.
Bioluminescence signal was analyzed as percentage of light 
units per tissue relative to the total number of light units per 
mouse. Total bioluminescence signal for LNs, tissues, and organs 
were calculated as the sum of the light units in each tissue. Values 
of bioluminescence signal below 10,000 light units were consid-
ered negative.
statistical analysis
Data are presented as the interquartile range (p75, upper edge; 
p25, lower edge; p50, midline; p95, line above the box, and p5, 
line below the box). Normal distribution was analyzed by the 
Shapiro-Wilks test. Non-parametric techniques (Mann–Whitney 
U test) were used (with Bonferroni adjustment). Analysis was 
performed using the software Stata 11 (StataCorp, USA) and 
GraphPad Prism 5.00 for Windows program (GraphPad Software, 
San Diego, CA, USA).
resUlTs
The Majority of the intranodally injected 
luci-eascs remain in the lns 48 h 
Postinfusion
In the present study, we investigated the biodistribution of the 
Luci-eASCs after IN administration in an experimental model of 
acute intestinal inflammation induced by TNBS which displays 
human inflammatory bowel disease-like clinical, histopathologic, 
and immunologic features (46).
Human adipose-derived MSCs expressing the luciferase 
gene were generated by using retrovirus-based methods 
(See Materials and Methods). To confirm the ASC character-
istics of the transduced Luci-eASCs, immunophenotyping by 
flow cytometry and in  vitro immunosuppression assays were 
carried out. As expected, Luci-eASCs were positive for CD73, 
CD90, and CD105 and negative for CD14, CD34, CD45, and 
HLA-DR according to the criteria of the International Society 
for Cellular Therapy (43) (Figure S1A in Supplementary 
Material). To evaluate the immunosuppression capacity of 
Luci-eASCs, T-cell proliferation assays were carried out with 
CFSE-labeled PBMCs stimulated with microbeads coated with 
anti-CD3/CD2/CD28 antibodies in the presence or absence 
of untransduced eASCs or Luci-eASCs (ratio eASCs:PBMCs, 
FigUre 1 | Analysis of total bioluminescence signal of Luci-eASCs in lymph 
nodes (LNs) and in tissues and organs at 48 h following intranodal 
administration. Sums of bioluminescence signals measured at 48 h as 
percentage of light units per LN (inguinal, popliteal, parathymic, parathyroid, 
mesenteric, caudal, and axillary included) and per tissue and organ (liver, 
spleen, intestine, lungs, heart, and blood included) relative to the total 
number of light units per mouse were expressed. Data are presented by dots 
and box-plots that represent the interquartile range (p75, upper edge; p25, 
lower edge; p50, midline; p95, line above the box; and p5, line below the 
box) of the percentage of total bioluminescence signal. Significance was 
analyzed by the Mann–Whitney U test and represented by *p < 0.05, 
**p < 0.01, and ***p < 0.001. Results correspond to four independent 
experiments.
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1:25). Proliferation of viable CD3+ T cells was determined at 
120 h by flow cytometry. Luci-eASCs inhibited T-cell prolifera-
tion at similar levels as the untransduced eASCs (Figure S1B in 
Supplementary Material).
Initial experiments were set up to define for how long the 
bioluminescence signal of the infused Luci-eASCs can be 
detected in vivo. A total of 3.2 × 105 Luci-eASCs were injected 
through the inguinal LNs into healthy mice. The biolumines-
cence signals were monitored at different time points. As shown 
in Figure S2A in Supplementary Material, the bioluminescence 
signal declined very rapidly within the first 72 h period from 
the infusion of the Luci-eASCs. Therefore, 48  h postinfusion 
of Luci-eASCs was chosen as the best time-point that allows 
analyzing in  vivo the biodistribution of the infused injected 
Luci-eASCs.
At 48  h postinfusion of the Luci-eASCs, the highest bio-
luminescence signals were measured in the LNs analyzed in 
this study (popLN, thymLN, thyrLN, mLN, cLN, axLN, and 
iLN), both in healthy [92.0 (70.3–99.2)%] and in TNBS-colitic 
mice [57.5 (46.8–79.6)%], whereas lower levels of the biolu-
minescence signals were detected in other organs and tissues 
analyzed (liver, spleen, intestine, lungs, heart, and blood) 
in both healthy [0.6 (0.3–2.6)%] and TNBS-colitic mice [2.8 
(0.8–5)%] (Figure  1; Figure S2 in Supplementary Material). 
Interestingly, in TNBS-colitic mice, a significant increase of 
the bioluminescence signal in the tissues and organs studied 
was detected in comparison with healthy mice. This paralleled 
with a decrease in the bioluminescence signal in the LNs of 
TNBS-colitic mice when compared to healthy mice (Figure 1). 
These results show that the majority of the infused Luci-eASCs 
remain in the LNs, 48 h postinfusion and that the inflamma-
tory challenge with TNBS, enhance the trafficking of a small, 
but significant, proportion of the infused-Luci-eASCs to other 
tissues and organs.
intranodal administered luci-eascs 
remained in the ilns and, Upon 
inflammation, a small Proportion of luci-
eascs Traffics to the intestine
To further dissect the biodistribution of the Luci-ASCs and 
how an acute inflammatory challenge may impact their homing 
toward the inflamed tissues, the bioluminescence signals were 
analyzed separately in the LNs (inguinal, popliteal, thymic, 
thyroid, mesenteric, caudal, and axillary LNs) and in the tissues 
and organs (liver, spleen, intestine, lung, heart, and peripheral 
blood). As shown in Figure 2A and Figure S2C in Supplementary 
Material, when Luci-eASCs were administered IN, most of the 
bioluminescence signal was found in the iLNs [87.5 (61.5–93.2)% 
in healthy mice and 51.4 (42.3–68.1)% in TNBS-colitic mice, 
p = 0.0011] where the Luci-eASCs were injected. In contrast, very 
low levels of the bioluminescence signals [0.4 (0.2–1.3)%] were 
measured within the lymphatic system with no clear preference 
for any of the LNs analyzed (Figure 2A).
Moreover, high bioluminescence signals were also detected 
in the adipose tissue surrounding the iLNs [5.9 (0.3–35.9)% 
in healthy mice and 37.4 (11.9–46.7)% in TNBS-colitic mice, 
Figure 2B; Figure S2D in Supplementary Material]. This suggests 
that after IN administration of the Luci-eASCs, the majority of 
the cells remained at the injection site either inside the LNs or in 
the adipose tissue associated to the LNs.
The bioluminescence signals in the other tissues and organs 
analyzed were very low (below 3%). The bioluminescence signal 
found in the intestine was significantly increased in TNBS-
colitic mice [1.5 (0.5–4)%] in comparison with the healthy mice 
[0.3 (0.1–0.7)%, p = 0.0037]. Increased bioluminescence signals, 
but not significant, were found in the liver [0.28 (0.04–0.80)%], 
spleen [0.10 (0.01–0.27)%], lungs [0.10 (0.02–0.30)%], and 
blood [0.14 (0.03–0.30)%] of the TNBS-colitic mice in com-
parison with the healthy mice [0.050 (0.008–0.531)%, 0.05 
(0.02–0.35)%, 0.04 (0.01–0.12)%, and 0.009 (0.000–0.065), 
respectively, Figure 2C; Figure S2D in Supplementary Material]. 
Additionally, the bioluminescence signal found in the intestine 
[1.5 (0.5–4)%] was significantly increased in comparison with 
the other tissues and organs analyzed in the TNBS-colitic mice 
FigUre 2 | Continued
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[0.28 (0.04–0.80)% for liver, 0.10 (0.01–0.27)% for spleen, 0.10 
(0.02–0.30)% for lungs, 0.038 (0.001–0.305)% for heart, and 0.14 
(0.03–0.30)% for blood].
Overall, these data indicate that when the Luci-eASCs were 
administered IN, the majority of the cells remained at the site 
of injection, either in the iLNs or the adipose tissue adjacent the 
FigUre 3 | Body weight changes in healthy and TNBS-colitic mice. Fold change in body weight from 24 to 48 h after intranodal (IN) administration are represented. 
(a) As controls, mice infused with the Luci-eASC IN with or without intrarectal 50% EtOH (vehicle of the TNBS). Healthy + Luci-eASCs IN, n = 16; EtOH + Luci-
eASCs, n = 10; TNBS, n = 14; TNBS + Luci-eASCs IN = 26. (B) Stratification of in vivo responses to treatment with Luci-eASCs administration IN in TNBS-colitic 
mice according to the fold change in body weights from 24 to 48 h. Colitic mice treated with Luci-eASCs were grouped into “responders” (Rs mice that did not lose 
weight at 48 h in comparison with 24 h) and “non-responders” (NRs mice that lost weight at 48 h in comparison with 24 h). TNBS, n = 14; TNBS + Luci-eASCs IN 
Rs, n = 15 and TNBS + Luci-eASCs IN NRs, n = 11. Data are presented by dots and box-plots that represent the interquartile range (p75, upper edge; p25, lower 
edge; p50, midline; p95, line above the box; and p5, line below the box) of the weight fold change at 48 h in comparison with the day 0. Significance was analyzed 
by the Mann–Whitney U test and represented by *p < 0.05 and ***p < 0.001. Results correspond to four independent experiments.
FigUre 2 | Continued  
Analysis of total bioluminescence signal of Luci-eASCs in the different lymph nodes (LNs) (inguinal, popliteal, parathymic, parathyroid, mesenteric, caudal, and 
axillary), adipose tissue adjacent the inguinal LNs and main tissues and organs (liver, spleen, intestine, lungs, heart, and blood) at 48 h. Bioluminescence signals 
measured at 48 h in the inguinal LNs (iLN), popliteal (popLN), parathymic (thymLN), parathyroid (thyrLN), mesenteric (mLN), caudal (cLN), and axillary (axLN)  
(a), adipose tissue surrounding the iLNs (B), and in the liver, spleen, intestine, lungs, heart, and blood (c) [Healthy + Luci-eASCs intranodal (IN), n = 12; 
TNBS + Luci-eASCs IN n = 25] were expressed as percentage of light units per tissue relative to the total number of light units per mouse. Data are presented by 
dots and box-plots that represent the interquartile range (p75, upper edge; p25, lower edge; p50, midline; p95, line above the box, and p5, line below the box) of 
the percentage of total bioluminescence signal. Significance was analyzed by the Mann–Whitney U test and represented by *p < 0.05, **p < 0.01, and ***p < 0.001. 
Results correspond to four independent experiments.
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iLNs. Only 0.4 (0.2–1.3)% of the bioluminescence signal was 
found in the rest of LNs analyzed with no clear preference for 
any of them. Although the amount of Luci-eASCs that migrate to 
the other tissues and organs analyzed was very low, there was a 
significant increase in the bioluminescence signal in the intestine 
in TNBS-colitic mice.
expanded adipose-Derived Msc 
administration by the in route Protects 
against TnBs-induced colitis
To investigate if the IN administration of Luci-eASCs can 
modulate acute inflammation, colitis was induced by administra-
tion of TNBS. One hour after the inflammatory challenge was 
induced, Luci-eASCs were infused IN. Body weights of mice were 
monitored within the first 48 h as the most meaningful physi-
ological parameter for monitoring acute intestinal inflammation. 
As shown in Figure  3A, TNBS-treated mice had a significant 
reduction in their body weights [−0.92 (−1.49 to −0.36)] fold 
weight change in comparison with control mice [healthy mice, 
−0.26 (−0.71 to 0.00) fold body weight change and mice treated 
with intrarectal 50% EtOH as the vehicle for the TNBS, −0.13 
(−0.32 to 0.25) fold body weight change]. The group of colitic 
mice treated with Luci-eASCs did not lose weight at 48 h after the 
inflammatory challenge [0.26 (−0.74 to 0.79)] in comparison to 
the untreated colitic mice.
These results demonstrate that, for the first time, the IN 
administration of eASCs is feasible and that can modulate effi-
ciently acute intestinal inflammatory responses.
increased amount of luci-eascs Within 
the lymphatic system can Be correlated 
with an improved immunomodulation
To investigate whether a correlation between the biodistribution 
of the Luci-eASCs and the modulation of the inflammation exists, 
FigUre 4 | Analysis of total bioluminescence signal of Luci-eASCs in lymph 
nodes (LNs) and in tissues and organs at 48 h in “responder” and 
“non-responder” TNBS-colitic mice treated with Luci-eASCs. Sum of 
bioluminescence signals measured at 48 h as percentage of light units per 
LN (inguinal, popliteal, parathymic, parathyroid, mesenteric, caudal, and 
axillary included) and per each tissue and organ (liver, spleen, intestine, 
lungs, heart and blood included) relative to the total number of light units per 
mouse were analyzed. Healthy + Luci-eASCs intranodal (IN), n = 13; 
TNBS + Luci-eASCs IN Rs n = 15; TNBS + Luci-eASCs IN NRs n = 11. 
Data are presented by dots and box-plots that represent the interquartile 
range (p75, upper edge; p25, lower edge; p50, midline; p95, line above the 
box; and p5, line below the box) of the percentage of total bioluminescence 
signal. Significance was analyzed by the Mann–Whitney U test and 
represented by ***p < 0.001. Results correspond to four independent 
experiments.
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we used body weight changes between 24 and 48 h postinfusion 
of the Luci-eASCs as a parameter to stratify mouse responses 
to treatment with Luci-eASCs. In this sense, “responder” mice 
were those TNBS-colitic mice that did not lose, or even gained, 
weight between 24 and 48 h postinfusion of the Luci-eASCs [0.53 
(0.34–0.89) in comparison with the TNBS-colitic mice, −0.92 
(−1.49 to −0.36)]. “Non-responder” mice were those TNBS-
colitic mice that continued to lose weight 48 h after the infusion of 
the Luci-eASCs [−0.91 (−2.34 to −0.45)] in comparison with the 
colitic mice. According to this stratification criteria, when Luci-
eASCs were administered IN, 15 out of the 26 mice did not lose 
weight (responder mice). This means that 58% of mice treated 
with Luci-eASCs had a positive response to the treatment with 
Luci-eASCs (Figure 3B).
Additionally, we compared the bioluminescence signals in 
the tissues and organs and in the LNs in the “responder” and 
“non-responder” mice. As shown in Figure 4, no differences in 
the total bioluminescence signal were found neither in the LNs 
[56 (49.1–87.0)% in responder mice and 58.4 (46.1–77.1)% in 
non-responder mice] nor in the other tissues and organs studied 
[2.8 (0.8–5.2)% in responder mice and 2.8 (0.8–5.0)% in non-
responder mice], suggesting the lack of correlation between 
the modulation of acute inflammation in the intestine and the 
bioluminescence signal in LNs and other tissues and organs.
When the bioluminescence signal of Luci-eASCs was analyzed 
at the injection site, no significant differences were found between 
the responder and the non-responder mice, neither in the iLNs 
[50.8 (43.1–67.0)% for responders; 56.0 (40.0–72.3)% for non-
responder mice] nor in the iLN-adipose tissue [32.3 (9.2–47.0)% 
for the responder mice, 40.0 (22.1–48.5)% for the non-responder 
mice, Figures 5A,B].
In contrast to this, the bioluminescence signals were tended 
to increase in the popliteal and parathyroid LNs of the responder 
mice in comparison with the non-responder mice [0.7 (0.3–1.4) 
vs. 0.2 (0.1–0.5)% in popliteal and 0.9 (0.5–1.8) vs. 0.4 (0.2–0.6)% 
in the thyroid LNs, Figure 5A]. Also, the bioluminescence signal 
increased, but not significantly, in the parathymic and mesenteric 
LNs of the responder mice in comparison with the non-responder 
mice [0.56 (0.17–2.92) vs. 0.28 (0.10–0.97)% in parathymic and 
1.32 (0.66–2.920) vs. 0.44 (0.34–0.76)% in the mesenteric LNs, 
Figure 5A]. This suggests that, in some instances, the increase 
amount of Luci-eASCs within the lymphatic system can be cor-
related with a better immunomodulation of the inflammatory 
responses.
However, no clear differences were found in the biolumines-
cence signals in tissues and organs analyzed between responder 
and non-responder mice. Although, a tendency to increase the 
bioluminescence signal was found in the liver, spleen, lungs, 
heart and blood of responder mice in comparison with the 
non-responder mice. Also, there was a significant increase in the 
bioluminescence signal in the liver [0.37 (0.10–1.26)%] in com-
parison with the heart [0.17 (0.03–0.30)%] of the responder mice 
but not in the non-responder mice [0.05 (0.03–0.57) vs. 0.090 
(0.002–0.299)%, Figure 5C].
Overall, these data indicate that, in responder mice, an 
increase amount of Luci-eASCs is located within the lymphatic 
system as suggested by the increase bioluminescence signals 
found in the popliteal, parathymic, parathyroid, and mesenteric 
LNs in comparison with the non-responder mice. However, in the 
tissues and organs analyzed these differences were not observed, 
although increased bioluminescence signals were found in the 
inflamed intestine.
DiscUssiOn
The functional properties of the MSCs have become of great 
interest for the treatment of a variety of diseases (20, 47, 48). At 
present, it is unknown whether the therapeutic effects of MSCs 
are carried out by a small fraction of the administered MSCs 
that migrates to sites of inflammation or/and through distant 
induction of regulatory immune cells that, rapidly and subse-
quently, mediate immunomodulation and tissue repair (22). In 
any case, their therapeutic effects are linked to a final increase of 
myeloid and lymphoid cells with a regulatory phenotype in the 
secondary lymphoid tissues associated to the inflammation site 
(18, 19, 25, 26). Thus, we proposed, for the first time, the admin-
istration of eASCs directly into the LNs, in order to determine 
FigUre 5 | Continued
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FigUre 5 | Continued  
Analysis of total bioluminescence signal of Luci-eASCs in lymph nodes (LNs) (inguinal, popliteal, parathymic, parathyroid, mesenteric, caudal, and axillary), adipose 
tissue adjacent the inguinal LNs and in tissues and organs (the liver, spleen, intestine, lungs, heart, and blood) in “responder” and “non-responder” TNBS-colitic 
mice treated with Luci-eASCs at 48 h. Bioluminescence signals, measured at 48 h in the inguinal LNs (iLN), popliteal (popLN), parathymic (thymLN), parathyroid 
(thyrLN), mesenteric (mLN), caudal (cLN), and axillary (axLN) (a), the adipose tissue surrounding the iLNs (B), and in the liver, spleen, intestine, lungs, heart, and 
blood (c) in “responders” mice (that did not lose weight from 24 to 48 h) and “non-responders” mice (that lost weight from 24 to 48 h) were analyzed as percentage 
of light units per tissue relative to the total number of light units per mouse. Healthy + Luci-eASCs intranodal (IN), n = 12; TNBS + Luci-eASCs IN Rs n = 15; 
TNBS + Luci-eASCs IN NRs n = 11. Data are presented by dots and box-plots that represent the interquartile range (p75, upper edge; p25, lower edge; p50, 
midline; p95, line above the box; and p5, line below the box) of the percentage of total bioluminescence signal. Significance was analyzed by the Mann–Whitney U 
test and represented by *p < 0.05. Results correspond to four independent experiments.
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whether the IN administration of MSCs could be an alternative 
strategy to modulate inflammation. The IN (or intralymphatic) 
route is being extensively used in immunotherapy protocols 
for treatment of cancer (29–32) and allergy (33, 34). The data 
reported indicate that this route of administration is feasible and 
can be translated to the clinic (35–37). Additionally, Gil-Ortega 
et al. provided robust evidences that endogenous adipose stromal 
cells can traffic in vivo through lymphatic system and home to 
the LNs (28).
In this study, we observed that IN administration of Luci-
eASCs can modulate acute intestinal inflammation in a mouse 
model of colitis induced by TNBS as shown by the maintenance 
of the body weights of colitic mice at 48 h after infusion of the 
cells (Figure  3). To our knowledge, this is the first time that 
a single dose of 3.2  ×  105 eASCs show immunomodulatory 
effects in a mouse model of colitis induced by TNBS (10, 40, 
49–52). We cannot provide any reasonable explanation for the 
observation that 58% of eASC-treated mice have a positive 
response to the cell therapy. It should be noticed that the bio-
distribution analysis was conducted using a single IL infusion 
of the Luci-eASCs whereas the majority of studies aiming at 
modulating immune responses used multiple eASCs doses to 
achieve robust modulation of inflammation. Since the main 
goal of our study was to define the in  vivo biodistribution of 
eASCs infused intranodally in an inflammatory environment, 
we cannot exclude that multiple IL infusion of eASCs would 
achieve a complete response.
Furthermore, Mancheño-Corvo et  al. demonstrated that 
eASCs administered IN reduced systemic inflammation, in an 
experimental model of arthritis, by inducting CD25+Foxp3+CD4+ 
cells and IL10+CD4+ cells in the LNs and in the spleen (27).
In vivo biodistribution of MSCs is an important parameter to 
take into account when evaluating the efficacy of the cell therapy 
with MSCs. After intravenous administration, the most widely 
used route for MSCs in the clinic, the infused MSCs accumulate 
preferential in the lungs (24, 38) and this is generally accompa-
nied by a transient immunomodulatory effect (22, 26, 53–56) due 
to their short-term persistence in vivo regardless of their origin 
(syngeneic, allogeneic or, even, xenogeneic). This, obviously, 
might impact the bioavailability of the cells, their targeting to 
tissues and, probably, their long-term therapeutic efficacy (24). 
Thus, in this study, we proposed to study the biodistribution of 
the IN administration of MSCs which potentially may represent 
an alternative route of administration for MSCs. The number of 
MSCs that can be delivered inside the LN after IN administration 
is significantly greater than the number of cells that reach the 
LNs following their delivery through the blood stream. This may 
allow achieving therapeutic effects using a low dose of MSCs. 
This will have major implications to improve the safety of the cell 
therapy together with a significant reduction in the production 
costs.
In our study, we observed that, following the IN administra-
tion of the Luci-eASCs, the majority of the bioluminescence 
signal was found in the LNs (Figure 1) mainly at the injection site, 
either in the inguinal LNs or in the adipose tissue surrounding 
the iLNs where the cells were injected (Figures 2A,B; Figure S2C 
in Supplementary Material). Only 0.4 (0.2–1.3)% of the biolumi-
nescence signal was found in other locations within the lymphatic 
system with no clear preference for any of the LNs analyzed 
(Figure 2A). These results show that, by the IN administration of 
MSCs, a higher number of cells are within the lymphatic system 
when compared to intravenous administration (25, 41) which 
could improve their therapeutic effects.
Only 1.9 (0.4–4.1)% of the bioluminescence signal was found 
in the tissues and organs analyzed and, surprisingly, in TNBS-
colitic mice, a significant increase of the total bioluminescence 
signal was found with in comparison with the healthy mice. This 
paralleled with a decrease in the bioluminescence signal in the 
iLNs and in the adipose tissue surrounding the iLNs of TNBS-
colitic mice when compared to healthy mice (Figures 1 and 2), 
suggesting a rapid and preferential trafficking of the Luci-eASCs 
to the inflamed tissues and organs upon their IN administration. 
This increase of the bioluminescence signal corresponded mainly 
to the intestine and to a lesser extent to the liver, spleen, lungs, and 
blood of the Luci-eASC-treated colitic mice suggesting that, by 
the IN route, MSCs have a preferential migration to the inflamed 
tissues, similar to what was happened when MSCs are infused by 
other routes of administration (23–25).
Trying to know if the presence of the MSCs at the inflam-
mation site is necessary for the modulation of the immune 
responses, we investigated the correlation between the biodis-
tribution of the Luci-eASCs and the modulation of the inflam-
mation attending to the stratification criteria into “responders” 
and “non-responders” mice. These stratification criteria were 
done based on the body weights of the Luci-eASC-treated colitic 
mice. The increase amount of Luci-eASCs within the lymphatic 
system in the responder mice can be correlated with an improved 
immunomodulation (Figure  5). This increase amount of Luci-
eASCs within the lymphatic system was preferentially found 
in the popLNs, thyrLNs, thymLNs, and mLNs. We did not see 
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any correlation between the presence of the MSCs in the tissues 
and organs analyzed and the modulation of the inflammation, 
this result suggests that the presence of the Luci-eASCs in the 
intestine does not seem to be necessary to achieve an adequate 
modulation of the inflamed intestine.
In summary, all these results suggest that the presence of 
the Luci-eASCs within the lymphatic system is responsible for 
their immunomodulatory effects. The IN administration of the 
Luci-eASCs allows the trafficking of a small proportion of cells 
to the inflamed intestine; although, a direct correlation with their 
biological effects could not be established. Further, these results 
confirm our hypothesis that the immunomodulatory effects of 
the eASCs may take place in the LNs where the immunoresponses 
are orchestrated.
Based on these results and those reported in the accompanying 
manuscript (27), further investigations are warranted to assess 
the beneficial effect of the IN route in cell therapy protocols with 
eASCs for treatment of immunomediated disorders.
cOnclUsiOn
These data demonstrate the feasibility of using the IN route of 
administration to infuse eASCs for the treatment of intestinal 
inflammatory diseases since Luci-eASCs can modulate an acute 
intestinal inflammation.
After IN administration, the majority of the Luci-eASCs 
remained in the inguinal LNs where the cells were infused and 
only lower levels of bioluminescence signals were found in 
tissues and organs related to the inflammation. After intestinal 
inflammation, an increased trafficking of the Luci-eASCs to 
the inflamed organs was found. In some instances, the increase 
amount of Luci-eASCs within the lymphatic system can be cor-
related with an improved immunomodulation. Taken together, 
these results indicate that the IN administration of eASCs 
represents a novel route for administering eASCs in cell therapy 
protocols.
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FigUre s1 | Characterization of Luci-eASCs. (a) Luci-eASCs were 
characterized by flow cytometry using antibodies against CD73, CD90, CD105, 
CD14, CD34, CD45, and HLA-DR (gray color). The corresponding isotype 
controls for each surface marker are shown (white color). Histograms shown are 
representative of three experiments. (B) Representative histograms of 
T-lymphocyte proliferation are shown. CFSE-labeled peripheral blood 
mononuclear cells (PBMCs) were stimulated with anti-CD3/CD2/CD28-coated 
beads in the absence (gray color) or presence (white color) of transduced ASCs 
(Luci-eASCs, left) or untransduced eASCs (right), ratio 1:25 eASCs or 
Luci-eASC:PBMCs. Proliferation of the viable CD3+ T cells was monitored after 
120 h by flow cytometry.
FigUre s2 | In vivo imaging of Luci-eASCs after IN infusion of Luci-eASCs.  
(a) Representative images of total bioluminescence signal at 24 and 48 h when 
Luci-eASCs were administered intranodally in healthy mice. (B) Graph represents 
the decline of total bioluminescence signal (luciferase activity) at different time 
points after 3.2 × 105 Luci-eASCs were administered intranodally into healthy 
mice. (c) Representative images of bioluminescence signal at 48 h of left inguinal 
(iLN), right inguinal lymph nodes (LNs), popliteal (popLN), parathyroid (thyrLN), 
parathymic (thymLN), mesenteric (mLN), and axillary (axLN) lymph nodes.  
(D) Representative images of bioluminescence signal at 48 h in intestine, blood, 
lungs, heart, liver, spleen, and adipose tissue adjacent inguinal lymph nodes 
(iLNs AT).
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